Purchase this article with an account.
N. Puche, A. Glacet-Bernard, A. Zourdani, M. Gerard, C. Gabriel, G. Soubrane; Intravitreal Ranibuzimab for Macular Edema Secondary to Retinal Vein Occlusion : A Retrospective Study of 34 Eyes. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5409.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy and the safety of intravitreal ranibuzimab injection in eyes with macular edema secondary to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO).
Retrospective study of an interventional series of treated patients. The files of 33 consecutive patients (34 eyes, 15 CRVO, 19 BRVO) were analyzed. Intravitreal injections of 0.5 mg ranibuzimab were administered; re-treatment was based on best-corrected visual acuity (BCVA) changes and optical coherence tomography findings.
One to 4 injections were performed in each patient (mean, 2.3). Mean follow-up was 5 months. Mean baseline central retinal thickness (CRT) was 548 µm and mean BCVA was 20/160. After the first injection, CRT significantly decreased to 301 µm (p<0.01), BCVA improved to 20/80 (p<.001). Visual acuity continued to improve significantly after the following injection(s), and CRT continued to decrease. At the end of follow-up, CRT was 195 µm (p<0.01) and BCVA improved by 9 letters (p<0.01). No local or systemic adverse effect was detected. Final BCVA was better in BRVO than in CRVO (20/40 versus 20/100, p=.02). Visual improvement was correlated to the decrease in RCT (p=.002) for each injection. Visual improvement was not correlated to the age nor to the presence of peripheral retinal ischemia.
Intravitreal injection of ranibuzimab appeared to be a safe and effective option in the treatment of macular edema secondary to retinal vein occlusion. Longer follow-up is needed to to define the real place of this treatment in the management of RVO.
This PDF is available to Subscribers Only